ROVI Signs Letter of Intentions with Novartis for Production of Influenza Vaccines
Laboratorios Farmacéuticos Rovi (ROVI, Madrid, Spain) has signed a letter of intentions with Novartis Vaccines (Basel, Switzerland), aiming to explore a definitive agreement for the transfer of Novartis Vaccines? patented technology needed to produce vaccines against seasonal and pandemic influenza.
Laboratorios Farmacéuticos Rovi (ROVI, Madrid, Spain), pharmaceutical company engaged in the research, development, in-licensing, manufacturing, and marketing of small molecule and specialty biologic drugs, has signed a letter of intentions with Novartis Vaccines (Basel, Switzerland), aiming to explore a definitive agreement for the transfer of Novartis Vaccines’ patented technology needed to produce vaccines against seasonal and pandemic influenza.
According to the letter of intentions, ROVI and Novartis Vaccines would establish a joint venture that would market influenza vaccines in Spain. The details of the commercial agreement between ROVI and Novartis Vaccines will be stated after the definitive contracts are closed. This strategic alliance with Novartis Vaccines for the manufacturing and marketing of influenza vaccines in Spain could result in a long-term collaboration.
Novartis Vaccines produces vaccines for seasonal and pandemic flu using traditional technology based on incubation in eggs and technology based on cell culture. Both technologies can be used with adjuvant technology. The technology to be transferred to ROVI would be selected after a deep analysis of reliability and costs.
The letter of intentions comes within the framework of the protocol of intentions signed on June 10, 2009, by the Ministry of Health and Social Policy and by the Regional Ministries of Innovation, Science, Enterprise, and Health of the Government of Andalusia for the research of new technologies and the production of flu vaccines. This program includes the construction of a center for the research and production of vaccines against seasonal and pandemic influenza, and is being implemented to supply the Spanish population with flu vaccines, all according to the regulatory filing 110699 released June 30, 2009.
Regional Ministries of Innovation, Science and Enterprise, and Health of the Government of Andalusia and ROVI will construct the center for the research and production of vaccines in the Health Sciences Technology Park of Granada. Assuming that a definitive agreement is reached with Novartis, the plant would have annual manufacturing capacity of 10 million doses of seasonal flu vaccines, and 30 million doses of vaccines for pandemic flu.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Kyron.bio Raises €5.5M to Advance Precision Glycan Engineering for Safer Antibody Therapeutics
May 28th 2025Funding will support the company’s efforts to refine its proprietary glycan-engineering platform, expand its scientific and operational team, and advance preclinical studies of its engineered biologics.
